Using SBRT for reirradiation of ultra-central thoracic tumors
Official title: Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Run by Peking University Third Hospital · NCT05189054 · Data updated 2026-11-12
This study is testing if a special type of radiation therapy called SBRT can safely treat patients with tough-to-reach lung tumors that have come back after previous radiation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | May 1, 2022 |
| Main results expected | April 30, 2025 |
| Study ends | April 30, 2027 |
| Registry record updated | December 27, 2023 |
| Trial ID | NCT05189054 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a pathological diagnosis of malignant tumors located in the ultra-central chest, who have previously received radiotherapy and have controlled metastasis.
✕Probably not a fit
Patients with poor pulmonary function, severe underlying health conditions, or those expected to survive less than three months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) for patients with ultra-central thoracic malignant tumors that have previously undergone radiotherapy. The study aims to assess how SBRT can be utilized as a salvage treatment option, particularly for recurrent lung cancer lesions located near critical mediastinal structures. By focusing on high-dose delivery to the tumor while minimizing exposure to surrounding healthy tissues, the study seeks to determine the potential benefits and risks associated with this approach in a challenging clinical scenario.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients with recurrent ultra-central thoracic tumors who have limited alternatives.
How similar studies have gone: Some previous studies have indicated acceptable safety and efficacy of SBRT for similar conditions, but this specific application remains somewhat novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological diagnosis is malignant tumor. * The location of the target lesion belongs to the ultra-central type of chest. * The target lesion had a history of radiotherapy, and the lesion diameter is ≤ 5cm. * There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment. * KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy. Exclusion Criteria: * Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment. * The general condition is poor, and the expected survival time is less than 3 months. * Psychiatric patients or poor compliance, unable to cooperate to complete treatment. * For other reasons, the researcher believes that it is not suitable to participate in this trial.
Where it's running
-
Peking University Third Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Junjie Wang, M.D. — Peking University Third Hospital
- Study coordinator: Zhe Ji, M.D.
- Email: aschoff@163.com
- Phone: 008618710002823
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized neoantigen peptide vaccine for solid tumors
This trial will test whether a custom neoantigen peptide vaccine given with poly-ICLC and an anti-PD-1 drug can help the immune system fight solid tumors in adults with advanced or high-risk disease.
-
Spatially fractionated radiation for gynecologic cancers
This will try spatially fractionated radiation after external beam therapy to control cervical cancer or pelvic recurrences in people who can't have standard brachytherapy.
-
Targeted therapies for childhood and adolescent cancer
This study is testing if new targeted treatments based on the genetic makeup of tumors can help kids and teens with cancer feel better and improve their chances of recovery.
-
Registry for Online Adaptive Radiotherapy in Pelvic and Thoracic Tumors
This study is testing if a new type of radiotherapy that adapts to patients' changing needs can reduce side effects and improve outcomes for people with pelvic or thoracic tumors compared to standard treatment.
-
Treatment for recurrent and refractory solid tumors using IMA402
This study is testing a new treatment called IMA402 to see if it can help people with advanced solid tumors that haven't responded to other therapies.
-
Preventing second cancers with Dostarlimab treatment
This study is testing if the drug Dostarlimab can help prevent second cancers in people who are at high risk after finishing treatment for their first cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.